ASTRAZENECA : Buy rating from JP Morgan

Published on 02/06/2025 at 19:24

MarketScreener with dpa-AFX Analyser

James Gordon from JP Morgan retains his positive opinion on the stock with a Buy rating. The target price remains set at GBX 10720.

Latest news about AstraZeneca PLC

AstraZeneca RSV jab offers protection for premature babies in England	07-19	AN
Foreign firms' executives entangled in Chinese probes	07-18	RE
Foreign firms' executives entangled in Chinese probes	07-18	RE
FTSE 100 closes up despite "harsh" UK jobs data	07-17	AN
FTSE 100 closes up despite "harsh" UK jobs data	07-17	AN
AstraZeneca, Daiichi Sankyo Win FDA Breakthrough Therapy Designation for Breast Cancer Drug	07-17	MT
AstraZeneca: ninth breakthrough designation for Enhertu	07-17
Enhertu Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with Her2 Positive Metastatic Breast Cancer	07-17	CI
London stocks end lower on fears over Fed independence, focus turns to jobs data	07-16	RE
London stocks end lower on fears over Fed independence, focus turns to jobs data	07-16	RE
European Equities Close Mixed in Wednesday Trading; UK Inflation Rises 3.6%	07-16	MT
Britain's life sciences plan gets mixed reception from pharma industry	07-16	RE
Alexion Announces Update on CARES Phase III Clinical Programme of Anselamimab in Light Chain Amyloidosis	07-16	CI
Astrazeneca's Anselamimab Misses Primary Goal in Phase III Amyloidosis Trial, Shares Down	07-16	MT
AstraZeneca therapy for clearing protein deposits fails main goal in late-stage study	07-16	RE
AstraZeneca therapy for clearing protein deposits fails main goal in late-stage study	07-16	RE
ASTRAZENECA : JP Morgan remains its Buy rating	07-16	ZD
AstraZeneca rare disease antibody shy of main goal in trial	07-16	AN
AstraZeneca's Anselamimab Treatment Fails to Reach Primary Goal in Late-Stage Trial	07-16	DJ
AstraZeneca: mixed phase III trial results for anselamimab	07-16
AstraZeneca Says Phase 3 Trial for Amyloidosis Medication Fails to Meet Primary Endpoint	07-16	MT
AstraZeneca drug fails main goal of late-stage amyloidosis study	07-16	RE
AstraZeneca's Anselamimab in AL amyloidosis did not meet primary endpoint in overall patient population	07-16	RE
Barclays: AstraZeneca's Q2 Results to Demonstrate 'Resilience' Amid Headwinds	07-15	MT
European Equities Close Mixed in Monday Trading; EU Signals Readiness to Retaliate Against US Tariffs	07-14	MT